News

September 2017: News Briefs

Veltassa Approved in European Union Market In late July, Relypsa, Inc., announced that Veltassa® (patiromer) received approval from the European Commission for its Marketing Authorization Application. Patiromer is indicated for the treatment of hyperkalemia (elevated levels of blood potassium). Veltassa is the brand name for patiromer in both the United States and Europe; it is approved for marketing in all ... Read More »

Tolvaptan Reduces Incidence of Kidney Pain in Patients with ADPKD

Patients with autosomal dominant polycystic kidney disease (ADPKD) often experience pain, a symptom reported early in the course of the disease. The pain associated with ADPKD can be severe and a challenge to manage as well as a complication that has an adverse effect on a patient’s quality of life. ADPKD-related acute pain may be caused by cyst hemorrhage, infection, ... Read More »

Dialysate Potassium Level and Adverse Events in Patients on Hemodialysis

In patients requiring hemodialysis, sudden death is a leading cause of death; 27% of all deaths in that patient population are attributable to arrhythmic mechanisms. In patients on maintenance hemodialysis three times a week, these events tend to cluster in the period just prior to the first dialysis session of the week when fluid overload and levels of various uremic ... Read More »

Treating Children and Adolescents with ESRD: A Guide for Nephrologists

It is rare for children to be diagnosed with end-stage renal disease (ESRD); there are approximately 8500 children with ESRD in the United States, according to the most recent US Renal Data System report. Each year, approximately 1500 children in the United States develop ESRD; two-thirds of those patients initiate treatment with hemodialysis and one-third initiate treatment with peritoneal dialysis. ... Read More »

July/August 2017: Abstract Roundup

CHRONIC KIDNEY DISEASE Benefits of Phosphorus Binder Use among Non-Dialysis CKD Patients American Journal of Nephrology. 2017;45(5);431-441. It is unknown whether the benefits of phosphorus binders extend to patients with chronic kidney disease (CKD) but without end-stage renal disease. In a retrospective cohort study conducted by Simran Bhandari, MD, and colleagues, the researchers sought to evaluate phosphorus binder use and ... Read More »

July/August 2017: News Briefs

KDIGO Issues Updated Guidelines for Treatment of CKD-MBD In late June, the Kidney Disease Improving Global Outcomes (KDIGO) updated its Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). The update amends the 2009 KDIGO Clinical Practice Guideline and includes revised positions on standards of care for the treatment of secondary hyperparathyroidism ... Read More »

Fluid Overload in AKI Patients Receiving Continuous Renal Replacement Therapy

Critically ill patients often experience acute kidney injury (AKI), which despite advances in intensive care medicine, has poor prognosis. Patients with AKI are at significant risk for morbidity and mortality. Among patients with AKI, approximately 4% require renal replacement therapy and may receive continuous renal replacement therapy (CRRT) to achieve hemodynamic stability. A mainstay of management of critically ill patients ... Read More »

CMS Reimbursement Reform and Hospitalizations and Readmissions among Hemodialysis Patients

Many healthcare reforms rely on pay-for-performance (P4P) initiatives. In P4P models, quality of care affects the reimbursement received by the provider. Quality of care is determined by either deliver-of-care processes deemed important or achieving specific health outcomes. Recent P4P initiatives that target care processes include Centers for Medicare & Medicaid (CMS) programs that pay for transitional care management and long-term ... Read More »

Dietary Intervention to Reduce Vasopressin Secretion in ADPKD Patients

An estimated eight to ten percent of patients in the United States and Europe with end-stage renal disease (ESRD) are also affected by autosomal dominant polycystic kidney disease (ADPKD). At present, there are no treatments to prevent the development of ESRD in patients with ADPKD. Compared with healthy controls, ADPKD patients have impaired urine-concentrating ability and higher levels of arginine ... Read More »

May/June 2017: Abstract Roundup

Acute Kidney Injury Prepregnancy AKI Associated with Adverse Outcomes in Pregnancy Journal of the American Society of Nephrology. 2017;28(5):1566-1574 There are few data available on the effect of clinically recovered acute kidney injury (AKI) on future pregnancy outcomes. Jessica Sheehan Tangren, MD, and colleagues retrospectively studied all women who delivered infants between 1998 and 2007 at Massachusetts General Hospital. The ... Read More »